VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma (NCT03556228)
A Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 as Monotherapy and in Combination With Pembrolizumab in Subjects With Solid Tumors or Lymphoma
🩺 Plain-English Summary (8th-Grade Level)
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists
Who can join: Review the eligibility criteria below.
Location: Providence Medical Foundation (site 209) — Santa Rosa, California
Age range: 18 Years to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (15 Sites)
- Providence Medical Foundation (site 209) — Santa Rosa, California
- Hartford Hospital (site 210) — Hartford, Connecticut
- The George Washington University Cancer Center (site 212) — Washington D.C., District of Columbia
- Holy Cross Hospital (site 213) — Fort Lauderdale, Florida
- Memorial Cancer Institute at Memorial Healthcare Systems (site 132) — Pembroke Pines, Florida
- Englewood Hospital and Medical Center (site 202) — Englewood, New Jersey
- Summit Medical Group (site 205) — Florham Park, New Jersey
- Atlantic Health System, Morristown Medical Center (site 124) — Morristown, New Jersey
- Presbyterian Kaseman Hospital (site 208) — Albuquerque, New Mexico
- Weill Cornell Medicine, Cornell University (site 126) — New York, New York
- Taylor Cancer Research Center (site 204) — Maumee, Ohio
- Cancer Care Associates of York (site 206) — York, Pennsylvania
- The University of Texas MD Anderson Cancer Center (site 127) — Houston, Texas
- Utah Cancer Specialists (site 203) — Salt Lake City, Utah
- PanOncology Trials, Hospital Oncologico - Puerto Rico Medical Center, Río Piedras (site 200) — San Juan,
📞 Contact the Study Coordinator
Phone: (510) 270-2790
Email: OM@VMOncology.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Head and Neck Carcinoma
- Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study — Phoenix, Arizona
- Neurofeedback in Decreasing Acute Radiotherapy-Induced Pain in Patients With Head and Neck Cancer — Houston, Texas
- Interdisciplinary Interventions to Address Pain Management Among Head and Neck Cancer Patients — Houston, Texas
- Clinical Data Collection in Studying Clinical Factors Associated With Post-Surgery Chronic Opioid Use in Patients With Head and Neck Cancers — Houston, Texas
- Medical Data Collection of Patients With Head and Neck Cancer Treated With Proton Therapy — Houston, Texas
- Dyadic Yoga Intervention for the Improvement of Healthcare Utilization and Quality of Life in Patients With Head and Neck Cancer Undergoing Chemoradiation and Their Caregivers — Houston, Texas
Explore by condition: All Head and Neck Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.